Cargando…

Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression

BACKGROUND: The validity of circulating tumour DNA (ctDNA) as an indicator of disease progression compared to medical imaging in patients with metastatic melanoma requires detailed evaluation. METHODS: Here, we carried out a retrospective ctDNA analysis of 108 plasma samples collected at the time of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marsavela, Gabriela, McEvoy, Ashleigh C., Pereira, Michelle R., Reid, Anna L., Al-Ogaili, Zeyad, Warburton, Lydia, Khattak, Muhammad A., Abed, Afaf, Meniawy, Tarek M., Millward, Michael, Ziman, Melanie R., Calapre, Leslie, Gray, Elin S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810871/ https://www.ncbi.nlm.nih.gov/pubmed/34373567 http://dx.doi.org/10.1038/s41416-021-01507-6

Ejemplares similares

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
por: Calapre, Leslie, et al.
Publicado: (2018)

Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies
por: McEvoy, Ashleigh C., et al.
Publicado: (2019)

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection
por: Marsavela, Gabriela, et al.
Publicado: (2020)

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2020)

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
por: Calapre, Leslie, et al.
Publicado: (2019)

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
por: Warburton, L., et al.
Publicado: (2020)

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
por: Clark, Michael E., et al.
Publicado: (2020)

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
por: Aya-Bonilla, Carlos Alberto, et al.
Publicado: (2020)

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
por: Warburton, Lydia, et al.
Publicado: (2020)

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma
por: McEvoy, Ashleigh C., et al.
Publicado: (2017)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device
por: Aya-Bonilla, Carlos A., et al.
Publicado: (2017)

Detection of metastases using circulating tumour DNA in uveal melanoma
por: Beasley, Aaron B., et al.
Publicado: (2023)

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
por: Abed, Afaf, et al.
Publicado: (2020)

Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients
por: Asante, Du-Bois, et al.
Publicado: (2023)

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies
por: Calapre, Leslie, et al.
Publicado: (2023)

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment
por: Gray, Elin S, et al.
Publicado: (2015)

SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes
por: Calapre, Leslie, et al.
Publicado: (2017)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

Associations of Physical Activity and Exercise with Health-related Outcomes in Patients with Melanoma During and After Treatment: A Systematic Review
por: Crosby, Brendan J., et al.
Publicado: (2021)

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients
por: Asante, Du-Bois, et al.
Publicado: (2021)

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
por: Klinac, Dragana, et al.
Publicado: (2013)

Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma
por: Beasley, Aaron, et al.
Publicado: (2018)

Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo
por: Calapre, Leslie, et al.
Publicado: (2016)

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma
por: Klinac, Dragana, et al.
Publicado: (2014)

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
por: Gray, Elin S., et al.
Publicado: (2015)

Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles
por: Aya-Bonilla, Carlos, et al.
Publicado: (2019)

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells
por: Freeman, James B, et al.
Publicado: (2012)

Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Acheampong, Emmanuel, et al.
Publicado: (2020)

A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision
por: Stark, Mitchell S., et al.
Publicado: (2019)

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
por: Acheampong, Emmanuel, et al.
Publicado: (2019)

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
por: Neumann, Martin H.D., et al.
Publicado: (2018)

Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma
por: Dunkel, Ying, et al.
Publicado: (2018)

Primary Aspergillosis of Bilateral Laryngoceles
por: Al-Ogaili, Zeyad, et al.
Publicado: (2014)

Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
por: Acheampong, Emmanuel, et al.
Publicado: (2022)

The radiologic progression of ameloblastomas
por: Merbold, Lene, et al.
Publicado: (2023)

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
por: Pedersen, Jesper Geert, et al.
Publicado: (2020)

ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
por: Romero, Atocha, et al.
Publicado: (2020)

Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression
por: Lau, Edmund, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c41smfsna4833rd0ef6bbn90mi